On January 14, 2022 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australianbased clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology, reported to release its first Annual Newsletter as a listed entity for the calendar year ending 31 December 2021 (Press release, Clarity Pharmaceuticals, JAN 14, 2022, View Source [SID1234605475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Despite the unprecedented challenges imposed by the global pandemic, this year has been extraordinary for Clarity.

Not only have we completed the largest biotechnology Initial Public Offering (IPO) on the Australian Securities Exchange (ASX), raising $92 million, but also significantly progressed clinical development of our pipeline of Targeted Copper Theranostics (TCT), commencing three new trials this year (including two trials in prostate cancer), closing a diagnostic trial of SAR-Bombesin following the exciting preliminary results, and expanding the theranostic trial in neuroblastoma to five sites. To support our clinical growth and take full advantage of therapeutic, manufacturing and logistical benefits of TCT, Clarity has been actively extending its manufacturing and logistical footprint. We have also progressed our preclinical and discovery programs and continued bolstering our IP portfolio to support the comprehensive platform of TCT.

Our team is excited to further build on the important milestones we have achieved to date and continue delivering on our ultimate goal of developing better treatments for children and adults with cancer in the new year